



November 9, 2022
JCR Pharmaceuticals Co., Ltd.

Translation

**Notice of completion of Kobe Science Park Center
-To integrate plant system for contract manufacturing of vaccines in a pandemic
emergency and strengthen the manufacturing capacity of JCR's products -**

Nov. 9, 2022 -- [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that it has completed construction of the new API plant "Kobe Science Park Center ("KSPC")" at the Kobe Science Park in Nishi-ku, Kobe.



The KSPC is an API plant built to satisfy the public solicitation requirements per the State of Emergency Vaccine Production System Improvement Project by the Ministry of Health, Labour and Welfare (MHLW). JCR must secure a system to manufacture vaccines and other remedies at least until the end of March 2030 (Click [here](#) for a related news release) in case of a future pandemic. The KSPC will allow JCR the production of vaccines and to contribute to a rapid and stable supply, in case of such a pandemic emergency.

In the absence of requests to manufacture vaccines etc., JCR will use the facility to research and develop to manufacture biopharmaceutical drugs for rare diseases, mainly lysosomal storage disorders (LSDs) applying its proprietary blood-brain-barrier (BBB) penetration technology J-Brain Cargo®. The KSPC will be equipped with four 2,000L single-use bioreactors. With the KSPC in full operational mode, JCR will be able to manufacture investigational drugs for several planned global clinical trials for LSDs in the next few years. Furthermore, JCR will also actively work to build a global supply chain with a view of potential future commercial demand.

[Facility Overview]

Name: Kobe Science Park Center
Address: 3-7-15, Ibukidai Higashimachi,
Nishi-ku, Kobe City
Completion date: November 4, 2022
Site Area: 19,991.17 m²
Total floor area: 14,585.66 m²
(office building three stories/
manufacturing 2 areas)
Start of operation: During the first quarter of
FY2023 (planned)



JCR will continue to further enhance our business activities and contribute to the treatment of as many patients as possible.

This matter has been factored into JCR's consolidated financial results for the year ending March 31, 2023.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice.

Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###